Authorized purpose: Assist radiologists in detecting solid and subsolid pulmonary nodules during review of multivendor multi-detector CT examinations of the chest; the device is an adjunctive first- or second-reader tool.
Clinical role
Concurrent first-reader support followed by full radiologist review, or second-reader support after the initial read; solid-only mode filters suspected subsolid and fully calcified findings.
Images and patients
CT/CTA · Chest/Lung
Key limitation
Keep in mind: The device is an adjunct and requires full radiologist review. The solid-only mode excludes potential subsolid and fully calcified findings. The FDA packet states that the algorithm has no user-interface component and that the hosting application is responsible for displaying CAD marks; the stated nodule sizes and 16-row recommendation bound the described device context.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Assist radiologists in detecting solid and subsolid pulmonary nodules during review of multivendor multi-detector CT examinations of the chest; the device is an adjunctive first- or second-reader tool.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest/Lung Input: Multivendor multi-detector chest CT examinations; the FDA device description specifies solid nodules of 3.0-30.0 mm and subsolid nodules of 5.0-30.0 mm average diameter, with 16 or more detector rows recommended.
Who uses it?Intended users: Radiologists and trained professionals who review thoracic CT examinations.
What does the software produce?Output: A list of nodule candidate locations sent to a visualization application or rendering component, which generates image series with CAD marks superimposed on thoracic CT images for radiologist review.
What is its most important limitation?Key limitation: The device is an adjunct and requires full radiologist review. The solid-only mode excludes potential subsolid and fully calcified findings. The FDA packet states that the algorithm has no user-interface component and that the hosting application is responsible for displaying CAD marks; the stated nodule sizes and 16-row recommendation bound the described device context.
Clinical takeaway. Clinical role: Assist radiologists in detecting solid and subsolid pulmonary nodules during review of multivendor multi-detector CT examinations of the chest; the device is an adjunctive first- or second-reader tool.
Evidence takeaway. Evidence from the reviewed source record: The standalone comparison used the same retrospectively collected 712 thoracic CT cases as the predicate evaluation: 232 UCLA cases, 145 original PMA cases, and 335 additional cases. There were 929 true nodules from 412 cases; across 3,560 lung lobes, 647 contained at least one true nodule and 2,913 contained none. Reference standards differed by source, using the UCLA reader study, 18-reader consensus for PMA cases, and 7-reader consensus for additional cases. The packet states that all primary and secondary endpoints were met but does not provide a single observed sensitivity, specificity, or AUC value in the reviewed text.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Assist radiologists in detecting solid and subsolid pulmonary nodules during review of multivendor multi-detector CT examinations of the chest; the device is an adjunctive first- or second-reader tool.
Concurrent first-reader support followed by full radiologist review, or second-reader support after the initial read; solid-only mode filters suspected subsolid and fully calcified findings.
Multivendor multi-detector chest CT examinations; the FDA device description specifies solid nodules of 3.0-30.0 mm and subsolid nodules of 5.0-30.0 mm average diameter, with 16 or more detector rows recommended.
A list of nodule candidate locations sent to a visualization application or rendering component, which generates image series with CAD marks superimposed on thoracic CT images for radiologist review.
The device is an adjunct and requires full radiologist review. The solid-only mode excludes potential subsolid and fully calcified findings. The FDA packet states that the algorithm has no user-interface component and that the hosting application is responsible for displaying CAD marks; the stated nodule sizes and 16-row recommendation bound the described device context.
The standalone comparison used the same retrospectively collected 712 thoracic CT cases as the predicate evaluation: 232 UCLA cases, 145 original PMA cases, and 335 additional cases. There were 929 true nodules from 412 cases; across 3,560 lung lobes, 647 contained at least one true nodule and 2,913 contained none. Reference standards differed by source, using the UCLA reader study, 18-reader consensus for PMA cases, and 7-reader consensus for additional cases. The packet states that all primary and secondary endpoints were met but does not provide a single observed sensitivity, specificity, or AUC value in the reviewed text.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The standalone comparison used the same retrospectively collected 712 thoracic CT cases as the predicate evaluation: 232 UCLA cases, 145 original PMA cases, and 335 additional cases. There were 929 true nodules from 412 cases; across 3,560 lung lobes, 647 contained at least one true nodule and 2,913 contained none. Reference standards differed by source, using the UCLA reader study, 18-reader consensus for PMA cases, and 7-reader consensus for additional cases. The packet states that all primary and secondary endpoints were met but does not provide a single observed sensitivity, specificity, or AUC value in the reviewed text.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
syngo.CT Lung CAD (Version VD30) regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K231157
Samplen=712
IndependenceIndependence not established
K231157
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231157. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Multivendor multi-detector chest CT examinations; the FDA device description specifies solid nodules of 3.0-30.0 mm and subsolid nodules of 5.0-30.0 mm average diameter, with 16 or more detector rows recommended.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA packet identifies a hosting visualization application such as syngo MM Oncology and the syngo.via framework as examples for displaying marks; it does not establish a universal PACS/RIS/EHR interface, current version compatibility, or local deployment configuration.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes syngo.CT Lung CAD as an algorithm without its own user interface, incorporated into a hosting application, with syngo.via listed as the hosting platform and syngo MM Oncology as the hosting application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "The software device is an algorithm which does not have its own user interface" … "The Hosting Application incorporating syngo.CT Lung CAD is responsible for implementing a user interface.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: A list of nodule candidate locations sent to a visualization application or rendering component, which generates image series with CAD marks superimposed on thoracic CT images for radiologist review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: A list of nodule candidate locations sent to a visualization application or rendering component, which generates image series with CAD marks superimposed on thoracic CT images for radiologist review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes syngo.CT Lung CAD as an algorithm without its own user interface, incorporated into a hosting application, with syngo.via listed as the hosting platform and syngo MM Oncology as the hosting application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The software device is an algorithm which does not have its own user interface" … "The Hosting Application incorporating syngo.CT Lung CAD is responsible for implementing a user interface.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The FDA packet identifies a hosting visualization application such as syngo MM Oncology and the syngo.via framework as examples for displaying marks; it does not establish a universal PACS/RIS/EHR interface, current version compatibility, or local deployment configuration.
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.
Siemens Healthineers' cybersecurity page states that its Cybersecurity Management Service maintains a product security inventory of over 1,000 product versions and over 21,000 monitored software components, with security whitepapers, SBOMs and vulnerability assessments delivered via teamplay Fleet, and that it operates incident and vulnerability management.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page names Siemens Healthineers generally and does not scope these commitments to any specific product release; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for syngo.CT Lung CAD (Version VD30); FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K231157 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.
Authorized purpose: Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.
Authorized purpose: Adjunctive detection of 3-20 mm pulmonary nodules in chest CT examinations for asymptomatic populations, including second-reader use.
AI-Rad Companion (Pulmonary) is image processing software that provides quantitative and qualitative analysis from previously acquired Computed Tomography DICOM images to support radiologists and physicians from emergency medicine, specialty care, urgent care, and general practice in the evaluation and assessment of disease of the lungs. It provides the following functionality: Segmentation and measurements of complete lung and lung lobes Identification of areas with lower Hounsfield values in comparison to a predefined threshold for complete lung and lung lobes Providing an interface to external Medical Device syngo.CT Lung CAD Segmentation and measurements of solid lung nodules. Dedication of found lung nodules to corresponding lung lobe. Correlation of segmented lung nodules of current scan with known priors and quantitative assessment of changes of the correlated data. Identification of areas with elevated Hounsfield values, where areas with elevated versus high opacities are distinguished. The software has been validated for data from Siemens Healthineers (filtered back projection and iterative reconstruction),GE Healthcare (filtered back projection reconstruction), and Philips (filtered back projection reconstruction).Only DI COM images of adult patients are considered to be valid input.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.